Cognios Beta Neutral Large Cap Fund LP Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cognios Beta Neutral Large Cap Fund LP lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 678 shares of the biopharmaceutical company’s stock after selling 67 shares during the quarter. Cognios Beta Neutral Large Cap Fund LP’s holdings in Regeneron Pharmaceuticals were worth $595,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in REGN. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $26,000. Fortitude Family Office LLC purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at about $31,000. MCF Advisors LLC increased its stake in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 12 shares in the last quarter. Criterion Capital Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $37,000. Finally, Sutton Wealth Advisors Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 38.2% in the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 13 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. TD Cowen lifted their price objective on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a report on Wednesday. Cantor Fitzgerald reissued a “neutral” rating and issued a $925.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, April 15th. Truist Financial restated a “buy” rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Finally, Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $977.77.

Insiders Place Their Bets

In other news, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the transaction, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the sale, the executive vice president now directly owns 13,789 shares in the company, valued at $12,888,716.19. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total transaction of $793,093.00. Following the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,325,338. The disclosure for this sale can be found here. Insiders have sold a total of 11,022 shares of company stock worth $10,552,991 in the last three months. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.1 %

REGN stock traded down $0.78 during midday trading on Wednesday, reaching $906.54. 369,734 shares of the company traded hands, compared to its average volume of 489,809. The firm has a market capitalization of $99.50 billion, a price-to-earnings ratio of 26.17, a P/E/G ratio of 2.59 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33. The business has a 50 day moving average of $951.41 and a 200-day moving average of $893.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. During the same period in the prior year, the firm posted $10.96 EPS. The firm’s revenue was up .6% compared to the same quarter last year. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.